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Our group has spearheaded research into the ‘non-specific
effects’ of vaccines in West Africa. Many observational
studies and lately randomized trials have shown that BCG
lowers all-cause mortality, particularly from septicaemia
and respiratory infections.1,2 These beneficial non-specific
effects are seen as long as BCG is the most recent vaccine.1–3
For this reason, a WHO-commissioned review of the non-
specific effects of vaccines specifically selected results for the
shortest period of follow-up, and where possible with cen-
soring for subsequent vaccines.4 In a meta-analysis of the
included studies, BCG versus no BCG was associated with a
47% [95% confidence interval (CI) ¼ 28-60%] reduction in
all-cause mortality. The other live vaccine under review,
measles vaccine, was likewise associated with large reduc-
tions in mortality; in contrast, most studies suggested that
the non-live diphtheria-tetanus-pertussis (DTP) vaccine was
associated with increased all-cause mortality. In 2014,
WHO recommended further research into the potential
non-specific effects of vaccines.5
Haahr et al. used a transient or temporary discontinu-
ation of neonatal BCG vaccination from 1991 to 1996
in Greenland to compare BCG-vaccinated and BCG-
unvaccinated birth cohorts with respect to infectious
disease hospitalizations (the vast majority being due to
respiratory infections) up to 3 years of age. They assumed
that the only potential birth cohort effect was the possible
BCG effect.6 This may not be correct; there were changes
in the timing of subsequent non-live vaccines, which were
also associated with birth cohort.6 Nonetheless, from 3
days to 3 months when BCG was the dominating vaccine,
having received neonatal BCG was associated with a 28%
(95% CI ¼ -6-51%) reduction in the risk of infectious dis-
ease hospitalizations,6 corroborating the findings from the
WHO review. Haahr et al. did however not emphasize this
result; instead they focused on the period from 3 months to
3 years of age.6 What is studied in this age group is not the
effect of neonatal BCG versus no BCG, but the effect of
receiving first neonatal BCG and then non-live vaccines
versus receiving non-live vaccines only. In this period,
BCG was associated with a 7% (-4-20%) increased risk of
infectious disease hospitalisation6 (test for similar BCG ef-
fect between 0-3 months and 3-35 months, P ¼ 0.05)
(Table 1).
The findings from Greenland are similar to the findings
from a recent cohort study in Finland using hospital admis-
sion data from before and after neonatal BCG vaccination
was stopped in 2006.7 The incidence rate ratio for
hospital-treated pneumonia for BCG-vaccinated children
was 0.73 (95% CI¼ 0.55-0.96) from birth and up to 3
months (before non-live vaccines were provided), versus
1.04 (0.89-1.20) from 3-12 months (test for interaction
0.03).7 The findings are also similar to the results of a re-
cent randomized trial in Denmark where the incidence rate
ratio for GP visits for suspected infection was 0.88 (95%
CI¼ 0.79-0.98) from birth to 3 months (again emphasizing
the period before non-live vaccines were given), versus 1.03
(0.97-1.09) from 3-13 months (test for interaction 0.01).8
The tendency for an age-differential effect of BCG was also
seen for parental-reported infection, strongest for parent-re-
ported fever [0.78 (0.52-1.03) before versus 1.05 (0.95-1.16)
after 3 months] and pneumonia [0.50 (0.17-1.46) versus
1.26 (0.99-1.60)].8 Thus, in the three studies from high-
income settings, which have data on the effect of neonatal
BCG on infectious diseases from birth to 3 months and
from 3 months onwards, there are striking similarities: the
effect of BCG was beneficial in the first months, but this
effect disappeared after the children received non-live
vaccines.
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Recent immunological studies have shed light on the im-
munological effects of BCG, demonstrating its ability to in-
duce epigenetic modifications at the monocyte level, leading
to generally increased innate immunity,9 which again trans-
lates into better protection against heterologous pathogens
and into increased immune responses to subsequent vac-
cines.10 These immunological effects may explain the obser-
vation that neonatal BCG could reduce the risk of infection
in the first months after BCG vaccination. They may also
explain why the effect disappears after non-live vaccines are
given; non-live vaccines have been associated with negative
non-specific effects on health,11 and receiving BCG before
could potentially amplify these negative non-specific effects
and be worse than receiving only the non-live vaccines.3
Thus, the findings from Greenland seem to fit very well into
the broader picture. Unfortunately, this conclusion is not
emphasized.
First, the results from 0-3 months are only presented as
a non-significant sensitivity analysis. Haahr et al. justify
the exclusion of the 0-3 month period ‘to avoid transient
misclassification of BCG vaccination due to delayed vac-
cination and to avoid lack of hospitalisation registration
caused by delayed registration of the infant’s CRS [Civil
Registration System] number’. However, elsewhere in the
paper they mention that ‘BCG vaccination is administered
within 48 hours of birth, except for children of low birth
weight (1.3%) or on the rare occasion when a delivery
does not take place at a hospital (1.6%)’6, making it clear
that transient misclassification of BCG should not be a
problem, and the authors have previously published that
the CRS is updated weekly.12 Thus, there appears to be no
strong need to exclude the most relevant follow-up period
and only present the results as a sensitivity analysis.
Second, when finding no beneficial effect on hospital
admissions in the 3-35 months age group, the authors con-
clude that ‘this study does not support the hypothesis that
neonatal BCG vaccination carries non-specific effects
reducing morbidity’. Thus, the paper gives the impression
of having refuted neonatal BCG having beneficial non-
specific effects—while actually refuting something else,
namely that neonatal BCG has beneficial non-specific ef-
fects after non-live vaccines have been given. In fact, the
most relevant analysis from 0-3 months of age, as well as
the reversal of the BCG effect from 0-3 months to 3-35
months in study by Haahr et al., both support that BCG
does more than prevent tuberculosis.
Unfortunately, it is not rare to dismiss a hypothesis by
using different exposures or outcomes or different method-
ologies from those used to formulate the hypothesis. WHO
has previously commissioned studies to test our findings
on negative non-specific effects of DTP vaccine. These
studies claimed to have found no negative effect of DTP.
However, it was later recognized that most studies used a
flawed methodology with survival bias,13 or they had given
BCG together with DTP. Thus, the studies did not answer
whether DTP had a negative non-specific effect.
The recent WHO review concluded that the non-
specific effects of vaccines warrant further study and that it
is important to involve many researchers.5 However, as
illustrated by the present example, it is very important that
all researchers test the relevant hypotheses using the appro-
priate methodology. In this case, the relevant questions are
whether BCG reduces infection until a non-live vaccine is
given, and whether the effect changes after administration
of non-live vaccines. In Greenland, Finland and Denmark,
it appears that neonatal BCG does reduce infection in the
first months of life, but may be associated with slightly
increased risk of infection after administration of non-live
vaccines.
Conflict of interest: We and the authors of the Haahr et al.
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Table 1. The effect of neonatal BCG versus no neonatal BCG vaccination on infectious disease morbidity from birth to 3 months
and from 3 months onwards
Study country Health outcome Young age group Older age group Interaction test for
similar neonatal
BCG effect in young
and older age group
Comparing BCG
versus no BCG
Comparing BCG then non-live
vaccines versus non-live vaccines
Greenland6 Hospital admission for infectious diseases 0.72 (0.49-1.06) 1.07 (0.96-1.20) 0.05
(3 days-< 3 months) (3-35 months)
Finland7 Hospital-treated primary pneumonia 0.73 (0.55-0.96) 1.04 (0.89-1.20) 0.03
(0-< 3 months) (3-12 months)
Denmark8 GP visits due to suspected infectious disease 0.88 (0.79-0.98) 1.03 (0.97-1.09) 0.01
(0-< 3 months) (3-13 months)
Parent-reported infectious disease 0.87 (0.72-1.05) 1.02 (0.97-1.07) 0.09
(0-< 3 months) (3-13 months)
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